Abstract
Erectile dysfunction is usually of vascular origin and is frequently encountered in men with cardiovascular disease. The introduction of phosphodiesterase-5 inhibitors has revolutionized the management of patients with erectile dysfunction. Currently available phosphodiesterase-5 inhibitors have distinct pharmacokinetic and pharmacodynamic properties, thus permitting for tailoring sexual therapy according to patient characteristics and needs. Phosphodiesterase-5 inhibitors possess vasorelaxing properties and exert systemic hemodynamic effects, which need to be taken into account when other cardiovascular drugs are co-administered. Special caution is needed with alpha-blockers, while the co-administration with nitrates is contra-indicated due to the risk of life-threatening hypotension. This review presents the advent of sexual therapy, describes the mechanism of action and the specific characteristics of commercially available phosphodiesterase-5 inhibitors, summarizes the efficacy and safety of these drugs with special emphasis on the cardiovascular system, and discusses the clinical criteria used for the selection of each drug for the individual patient.
Keywords: Cardiovascular risk, erectile dysfunction, female sexual dysfunction, phosphodiesterase-5 inhibitors, sildenafil, tadalafil, vardenafil.
Current Drug Targets
Title:PDE-5 Inhibitors: Clinical Points
Volume: 16 Issue: 5
Author(s): Michael Doumas, Antonios Lazaridis, Niki Katsiki and Vasilios Athyros
Affiliation:
Keywords: Cardiovascular risk, erectile dysfunction, female sexual dysfunction, phosphodiesterase-5 inhibitors, sildenafil, tadalafil, vardenafil.
Abstract: Erectile dysfunction is usually of vascular origin and is frequently encountered in men with cardiovascular disease. The introduction of phosphodiesterase-5 inhibitors has revolutionized the management of patients with erectile dysfunction. Currently available phosphodiesterase-5 inhibitors have distinct pharmacokinetic and pharmacodynamic properties, thus permitting for tailoring sexual therapy according to patient characteristics and needs. Phosphodiesterase-5 inhibitors possess vasorelaxing properties and exert systemic hemodynamic effects, which need to be taken into account when other cardiovascular drugs are co-administered. Special caution is needed with alpha-blockers, while the co-administration with nitrates is contra-indicated due to the risk of life-threatening hypotension. This review presents the advent of sexual therapy, describes the mechanism of action and the specific characteristics of commercially available phosphodiesterase-5 inhibitors, summarizes the efficacy and safety of these drugs with special emphasis on the cardiovascular system, and discusses the clinical criteria used for the selection of each drug for the individual patient.
Export Options
About this article
Cite this article as:
Doumas Michael, Lazaridis Antonios, Katsiki Niki and Athyros Vasilios, PDE-5 Inhibitors: Clinical Points, Current Drug Targets 2015; 16 (5) . https://dx.doi.org/10.2174/1389450115666141111111301
DOI https://dx.doi.org/10.2174/1389450115666141111111301 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cannabinoids: Occurrence and Medicinal Chemistry
Current Medicinal Chemistry Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy
Mini-Reviews in Medicinal Chemistry Atrial Tachycardias Occurring Late After Open Heart Surgery
Current Cardiology Reviews Pharmacokinetics of Drugs in Neonates: Pattern Recognition Beyond Compound Specific Observations
Current Pharmaceutical Design Artificial Blood: A Futuristic Dimension of Modern Day Transfusion Sciences
Cardiovascular & Hematological Agents in Medicinal Chemistry A Case Report of Necrotizing Fasciitis after Cesarean Delivery
Current Women`s Health Reviews Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights
Current Respiratory Medicine Reviews GHB, GBL and 1,4-BD Addiction
Current Pharmaceutical Design Ion Channel Architecture of the Renal Microcirculation
Current Hypertension Reviews Vascular Endothelin and Hypertension - From Receptors to Medicine
Current Hypertension Reviews Antioxidant Activity and Chemical Components as Potential Anticancer Agents in the Olive Leaf (Olea europaea L. cv Leccino.) Decoction
Anti-Cancer Agents in Medicinal Chemistry Oxytocin in the Heart Regeneration
Recent Patents on Cardiovascular Drug Discovery Significance of 1,3,4-Oxadiazole Containing Compounds in New Drug Development
Current Drug Research Reviews Hydrogen Peroxide Produced by Mitochondrial Monoamine Oxidase Catalysis: Biological Implications
Current Pharmaceutical Design Proniosomes in Transdermal Drug Delivery
Current Pharmaceutical Design Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights
Current Pharmaceutical Design Fibromyalgia Syndrome: Which Antidepressant Drug Should We Choose
Current Pharmaceutical Design Emerging Role of Cetuximab in the Treatment of Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Vascular Toxicity of Chemotherapeutic Agents
Current Vascular Pharmacology Eidtorial from Editor-in-Chief : [ Keeping up with Advances in Cardiovascular and Hematological Medicine in 2012 ]
Cardiovascular & Hematological Agents in Medicinal Chemistry